Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective

✍ Scribed by Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C.

• Book ID: 122122528
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 63 KB
• Volume: 16
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2013.08.2240